CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 3, May/June 2010
AFRICA
180
Boehringer Ingelheim has announced the
availability of a second brand of Micardis
®
(telmisartan). This unique angiotensin II
receptor (type AT
1
) antagonist is now
available alone and in combination with
hydrochlorothiazide (the active ingredi-
ents of Micardis
®
and Co-Micardis
®
) in an
additional and more affordable presenta-
tion pack. The new product is available
in a full dosage range and is known as
Pritor
®
40 mg, Pritor
®
80 mg, Co-Pritor
®
40/12.5 mg and Co-Pritor
®
80/12.5 mg.
Micardis
®
/Pritor
®
is one of the most
Advertorial
Boehringer Ingelheim launches a more affordable Micardis
®
studied antihypertensives in clinical trials
and is widely used, with over five million
patient years since its approval. Its safety
profile is similar to that of placebo.
Micardis
®
/Co-Micardis
®
and Pritor
®
/
Co-Pritor
®
are manufactured at the same
Boehringer Ingelheim factory inGermany.
Pritor
®
and Co-Pritor
®
are identical to the
original products, and will give South
African patients access to telmisartan at
a substantial price reduction compared
to that of Micardis
®
/Co-Micardis
®
. This
represents a significant cost saving for all
mild to moderate hypertensive patients
in South Africa. Patients, doctors and
pharmacists can have full confidence in
the quality, safety and efficacy of Pritor
®
and Co-Pritor
®
.
For more information contact Kim
Nagoor on +27 11 348-2519 or e-mail:
.
Note: The
Cardiovascular Journal of
Africa
has published a number studies
related to telmisartan. Visit
co.za or Pubmed for further data on this
anti-hypertension medication.
Cardiovascular Care Products
Trimega provides essential fatty acids
Trimega capsules contain the omega-3
essential fatty acids, namely eicos-
apentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), formulated in
a single gelatine-free capsule. Most
western diets are thought to be defi-
cient in these fatty acids.
In view of the latest overwhelm-
ing evidence of the benefit of these
fatty acids in the secondary preven-
tion of cardiovascular disease, Trimega
capsules have recently become avail-
able in South Africa.
Current AHA dietary guidelines
recommend combined EPA and DHA
in a dose of approximately 1 000 mg/
day in patients with coronary heart
disease, and Trimega in a twice-daily
dosage satisfies this criterion.
Trimega capsules contain 500 mg
of EPA and DHA per capsule (SABS
tested) and the raw material has been
certified free of heavy metals.
Further
information
from:
Pharmafrica (Pty) Ltd: 0800 601 098
toll free
